Pre-Conference Workshop | ICPoFiVD 2026 Next-Generation Precise Vaccine Development: From NGS to Industry-Ready Commercialisation
Nuevogenix Sdn. Bhd., in collaboration with the Institute of Bioscience, Universiti Putra Malaysia (UPM), in conjunction of The 2nd International Conference on Poultry and Fish Vaccinology and Diagnosis (ICPoFiVD) 2026 is proud to announce a 3 ½ -day intensive pre-conference workshop designed to provide participants with end-to-end, hands-on experience in next-generation vaccine development.
This workshop integrates viral genomics, bioinformatics, and multi-platform vaccine development strategies into a single practical pipeline, bridging the gap between academic research and commercialisation.
🔬 Workshop Highlights
Participants will gain exposure to:
- Multi-platform vaccine technology 🎓🛠️
- Data-driven vaccine design workflows 🎓🛠️
- Viral whole-genome sequencing 🛠️ 💬
- Phylogenetic analysis and strain characterisation 🛠️💬
- Gene target determination 🎓🛠️
- Case study– CRISPR based-live attenuated next generation vaccine 🎓🛠️💬
- Pre-commercialisation insights, including dossier preparation and regulatory considerations 🎓💬
📅 Workshop Details
- Dates: 14 – 17 April 2026
- Duration: 3 ½ Days (Pre-Conference Workshop)
- Venue: Institute of Bioscience, Universiti Putra Malaysia (UPM)
(Limited seat for 25 pax only)
The programme includes:
- Expert lectures
- Wet-lab practical sessions
- Dry-lab bioinformatics hands-on training
- Case-based discussions
🎯 Target Participants
This workshop is ideal for:
- Undergraduate and postgraduate students
- Academic researchers and lecturers
- Laboratory scientists and research officers
- Industry professionals in virology, vaccinology, biotechnology, and animal health
Recommended background:
- Molecular biology
- microbiology
- biotechnology
- veterinary science
- or related disciplines
🎓 Expected Outcomes
Participants will:
- Develop strong technical competency in modern vaccine development workflows
- Gain practical exposure to CRISPR-based viral engineering
- Understand regulatory and dossier requirements prior to commercialisation
- Receive a Certificate of Participation
💰 Participant Fees
| Type | Nationality | Participant Category | Fee / pax | Grouping |
|---|---|---|---|---|
| Early Bird (23/2 – 23/3/2026) | Local | Students | RM 1,800 |
10% off Regular Registration Fees Min of 3 pax from the SAME institutions Single group submission |
| Academic/Government Researchers | RM 2,200 | |||
| Industry Participants | RM 2,600 | |||
| International | Students | USD 500 | ||
| Academic/Government Researchers | USD 610 | |||
| Industry Participants | USD 700 | |||
| Regular Fee (24/3 – 14/6/2026) | Local | Students | RM 2,000 |
One invoice and payment Participant names fixed upon registration Not applicable to Early Bird fee |
| Academic/Government Researchers | RM 2,500 | |||
| Industry Participants | RM 3,000 | |||
| International | Students | USD 550 | ||
| Academic/Government Researchers | USD 650 | |||
| Industry Participants | USD 800 |
Fees include training, laboratory access, consumables, lunch & refreshments, and certification.
📩 Registration & Payment Information
🔗 Register here:
https://tinyurl.com/rhpp7cc6
📧 Important: Participants are required to request an invoice prior to making payment.
Please email: admin@nuevogenix.com
Payment Details
| Bank Name | Maybank Islamic Berhad |
|---|---|
| Account Name | Nuevogenix Sdn. Bhd. |
| Account Number | 5621 4281 6919 |
| SWIFT Code | MBISMYKL |
| Company Address |
Nuevogenix Sdn. Bhd. UPM-MTDC Technology Centre Jalan Maklumat, Universiti Putra Malaysia 43400 Serdang, Selangor, Malaysia |
Payment should only be made after receiving the official invoice.
📣 Why You Should Attend
This workshop offers a rare, end-to-end exposure to real vaccine development pipelines; from viral genome analysis to regulatory readiness, led by experts from academia and industry.
Designed in collaboration with the Institute of Bioscience, UPM (in conjunction of The 2nd ICPoFiVD 2026), this programme goes beyond theory to prepare participants for real-world vaccine R&D and commercialisation pathways.
Stay tune for more information and updates!
See you soon!